Ventral Hernia Prevention After Liver Transplantation

Status Recruiting

Clinical Trial Summary

This study aims to evaluate if the risk of developing ventral hernia after liver transplantation can be reduced through the prophylactic implantation of a synthetic, fully resorbable mesh "Phasix" in the course of liver transplantation. Patients will be randomized in a 1:1 ratio to receive either Phasix mesh or standard surgery without the use of Phasix. Ultra-sound examinations of the wound area will be performed 14 days, 3, 6 and 12 months after liver transplantation. Furthermore, presence of infections, seroma, pain and other problems in the wound area will be assessed.

Clinical Trial Description

Ventral hernia is a frequently occurring complication following liver transplantation, with a reported risk in the literature ranging from 5% to 25%. This study aims to evaluate if the risk of developing ventral hernia after liver transplantation can be reduced through the prophylactic implantation of a synthetic mesh "Phasix" in the course of liver transplantation. PHASIX™ Mesh is a fully resorbable mesh implant prepared from poly-4-hydroxybutyrate (P4HB). Absorption of the mesh material occurs within 12 to 18 months. Patients will be randomized in a 1:1 ratio to receive either Phasix mesh in the course of liver transplantation or standard surgery without the use of Phasix. Ultra-sound examinations of the wound area will be performed 14 days, 3, 6 and 12 months after liver transplantation. Furthermore, presence of infections, seroma, pain and other problems in the wound area will be assessed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03222102
Study type	Interventional
Source	Medical University of Graz
Contact	Daniela Kniepeiss, MD
Phone	0043 316 385 13893
Email	daniela.kniepeiss@medunigraz.at
Status	Recruiting
Phase	N/A
Start date	November 30, 2017
Completion date	March 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04180735` - Intestinal Perforation in Patients Receiving an Orthtopic Liver Transplantation in the Montpellier University Hospital
Completed	`NCT01011205` - Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation	Phase 3
Completed	`NCT01888432` - Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants	Phase 3
Recruiting	`NCT04203004` - HOPE With Cytokine Filtration in Liver Transplantation (Cyto-HOPE)	N/A
Recruiting	`NCT04564313` - Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation	Phase 1
Withdrawn	`NCT03596970` - Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.	Phase 3
Not yet recruiting	`NCT02544906` - Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation	N/A
Completed	`NCT03133065` - Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs	Phase 4
Recruiting	`NCT01705015` - Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement	N/A
Completed	`NCT01655563` - Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation	Phase 2
Terminated	`NCT01445236` - Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance	N/A
Completed	`NCT01425385` - Autoregulation Assessment During Liver Transplantation	N/A
Completed	`NCT00938860` - Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C	Phase 4
Completed	`NCT00531921` - Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival	N/A
Terminated	`NCT00585858` - Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant	N/A
Withdrawn	`NCT00585429` - Evaluation of Kidney Disease in Liver Transplant Recipients	N/A
Completed	`NCT00456235` - Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors	Phase 4
Recruiting	`NCT00147459` - Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation	N/A
Terminated	`NCT00161356` - Ambisome in Liver Transplant Patients	Phase 4
Withdrawn	`NCT00167492` - Enteric Coated Myfortic for Liver Transplant Recipients	Phase 4